巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02367 巨子生物

未开盘 09-07 16:08:16

26.000

-0.620

-2.33%

最高26.540	最低26.000	成交量158.42万
今开26.220	昨收26.620	日振幅2.03%
总市值276.12亿	流通市值276.12亿	总股本10.62亿
成交额4,135万	换手率0.15%	流通股本10.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":26,"timestamp":1788768496003,"preClose":26.62,"halted":0,"volume":1584242,"delay":0,"changeRate":-0.023290758827948947,"floatShares":1061999999,"shares":1061999999,"eps":2.1149457947441457,"marketStatus":"未开盘","change":-0.62,"latestTime":"09-07 16:08:16","open":26.22,"high":26.54,"low":26,"amount":41349817,"amplitude":0.020285,"askPrice":26.02,"askSize":600,"bidPrice":26,"bidSize":49400,"shortable":3,"etf":0,"ttmEps":1.8379216284524866,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788831000000},"marketStatusCode":0,"adr":0,"listingDate":1667491200000,"exchange":"SEHK","adjPreClose":26.62,"dividendRate":0.053446,"openAndCloseTimeList":[[1788744600000,1788753600000],[1788757200000,1788768000000]],"volumeRatio":0.511598,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02367","defaultTab":"news","newsList":[{"id":"2665398249","title":"【券商聚焦】中信建投：上半年收入与利润双增，医药行业步入新发展周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398249","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398249?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:04","pubTimestamp":1788743053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业整体收入与扣非净利润实现双增长，创新药、CXO、制药装备及科学试剂等板块积极复苏，行业步入新发展周期。创新药收入+58.68%，扭亏为盈，出海总金额超900亿美元，全年有望超越2025年水平，国际化持续兑现；CXO收入+25.2%，扣非净利润+66.5%，订单旺盛，上行周期确立。随着集采出清、创新放量、出海落地及上游国产化提升，行业有望开启高质量发展周期，龙头将持续受益。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","IE00BPRC5H50.USD","LU1720050803.USD","BK1515","IE00B3M56506.USD","09926","BK1585","01099","601066","LU0640798160.USD","LU2488822045.USD","02228","02367","BK1207","LU2476274308.USD","BK1141","LU0348827113.USD","BK1161","02268","BK1500","BK1593","LU0417516902.SGD","LU0828237510.HKD","LU1115378108.SGD","KURE","BK1100","LU0228659784.USD","LU1969619763.USD","KCE","HK0000165453.HKD","LU2476274720.SGD","06821","BK1191","BK1588","IE00B5MMRT66.SGD","LU2399975544.HKD","LU2778985437.USD","02196","03933","BK1583","LU1770034418.SGD","09688","06160","BK1197","SG9999004311.SGD","LU0588546209.SGD","LU0348825331.USD","LU2328871848.SGD","BK1574","01789"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664382615","title":"【券商聚焦】华源证券维持巨子生物（02367）买入评级 期待H2盈利拐点向上","url":"https://stock-news.laohu8.com/highlight/detail?id=2664382615","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664382615?lang=zh_cn&edition=full","pubTime":"2026-09-04 15:18","pubTimestamp":1788506304,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华源证券发布研报指，巨子生物 26H1实现收入29.2亿元，同比-6.3%；净利润9.4亿元，同比-20.5%；经调净利润9.5亿元，同比-21.5%。短期业绩承压，但伴随新品上市落地，下半年销售费用投入及净利率表现有望持续恢复，期待H2盈利拐点向上，维持“买入”评级。可丽金实现收入4.99亿元，同比几乎持平。华源证券预计2026-28年公司归母净利润为19.8/22.2/24.8亿元，同比增长+3.4%/12.2%/11.8%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990730","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","161027","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167453302","title":"巨子生物8月无新增发行或股份变动，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1167453302","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167453302?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:46","pubTimestamp":1788425195,"startTime":"0","endTime":"0","summary":"巨子生物控股有限公司于2026年9月3日披露了截至2026年8月31日的月度证券变动报告。报告显示，公司在本月内法定及注册股本、已发行股份及库存股份数量均保持不变。已发行股份总数依旧为1,061,704,000股，未出现任何新增发行、购回、注销或库藏股变动。公司在公告中确认，所有股份变动及披露均遵守香港联交所《上市规则》和相关法律法规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887532","title":"美妆股走强 毛戈平（01318）涨4% 机构指板块基本面稳步修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887532","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664887532?lang=zh_cn&edition=full","pubTime":"2026-09-01 10:39","pubTimestamp":1788230355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美妆股走强，毛戈平（01318）涨4.00%，上美股份（02145）涨3.32%，巨子生物（02367）涨1.86%。华龙证券近日研报指，政策层面，美妆行业监管优化与产业创新共振，化妆品新原料目录扩容持续降低企业研发备案门槛，同时推动AI技术、生物科技与护肤研发深度融合，行业高质量创新发展态势明确。当前板块基本面稳步修复，品牌出海、科技护肤等细分赛道机遇凸显。维持美容护理行业“推荐”评级。万联证券提到，消费分级时代，潮玩、古法金、国货美妆等情绪消费赛道景气度高企。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990193","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU2242644610.SGD","02145","LU0348766576.USD","LU0348767384.USD","BK1207","SG9999004311.SGD","LU0455707207.USD","LU0502904849.HKD","01318","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662780170","title":"巨子生物上半年营收净利双降：可复美业绩失速，可丽金未逆袭","url":"https://stock-news.laohu8.com/highlight/detail?id=2662780170","media":"南方都市报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662780170?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:18","pubTimestamp":1787649522,"startTime":"0","endTime":"0","summary":"近日，巨子生物发布2026年中期业绩公告，这份成绩单打破了市场此前对其重回增长的期待。公告显示，公司营业收入29.18亿元，同比下滑6.3%；归属于本公司权益股东的利润约为9.4亿元，同比下跌20.5%，经调整净利润约9.5亿元，同比下降21.5%，利润端的降幅显著高于营收端，这家顶着“重组胶原蛋白第一股”光环的昔日高增长明星企业，正在经历上市之后的业绩承压期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608253852927356.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608253852927356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661956225","title":"【券商聚焦】东北证券维持巨子生物（02367）买入评级 指公司研发壁垒深厚","url":"https://stock-news.laohu8.com/highlight/detail?id=2661956225","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661956225?lang=zh_cn&edition=full","pubTime":"2026-08-24 14:13","pubTimestamp":1787552035,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东北证券发布研报指，巨子生物 发布2026年中期业绩，2026H1实现营收29.18亿元，同比下降6.26%；净利润9.40亿元，同比下降20.50%；经调整净利润9.5亿元，同比下降21.5%。研报指出，分品牌看，可复美营收23.47亿元，占比80.4%，同比下降7.7%；可丽金营收4.99亿元，占比17.1%，同比仅微降0.8%，展现韧性。618大促中，可复美线上全渠道全周期GMV同比增长超过25%，可丽金同比增长超过30%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989129","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","02367","000686"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661470562","title":"砍掉达人直播后，巨子生物每卖100元货仍要花43元推销","url":"https://stock-news.laohu8.com/highlight/detail?id=2661470562","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661470562?lang=zh_cn&edition=full","pubTime":"2026-08-24 11:19","pubTimestamp":1787541561,"startTime":"0","endTime":"0","summary":"可复美一个品牌的收入下滑，就几乎吞噬了巨子生物全部的营收增量——这正是半年报里最刺眼的数据。上半年，这个占比超八成的超级单品收入从25.42亿元跌至23.47亿元，而公司整体营收不过从31.13亿元降至29.18亿元。为了摆脱对头部主播的依赖，巨子生物主动收缩达人直播渠道，代价是销售费用率飙升到43.4%，每挣100元就要花掉43元推销。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608243850893374.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608243850893374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02367","SG9999004311.SGD","LU2488822045.USD","BK1207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661257368","title":"港股异动 | 巨子生物(02367)再跌超6% 公司主动调整渠道结构 上半年业绩有所承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2661257368","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661257368?lang=zh_cn&edition=full","pubTime":"2026-08-21 14:21","pubTimestamp":1787293278,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，巨子生物(02367)再跌超6%，截至发稿，跌5.95%，报27.84港元，成交额1.18亿港元。消息面上，巨子生物发布业绩，上半年收入约29.18亿元，同比减少6.3%；归母净利润9.4亿元，同比减少20.5%。业绩承压主要系公司主动调整渠道结构，达人直播占比下降，以及加大品牌以及新品宣传，但公司仍聚焦长期经营质量、夯实渠道与产品竞争力。广发证券指出，低基数+新品放量，看好26H2增长修复。公司品牌势能企稳回升，两大主品牌618大促表现亮眼。未来护肤端看好超透棒等新品放量及渠道结构优化调整，医美端伴随胶原三类械商业化落地，有望打开第二增长曲线，驱动公司业绩重回增长轨道。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","SG9999004311.SGD","LU2488822045.USD","KCAI","BK4585","BK1207","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102026058","title":"异动解读｜巨子生物盘中下跌5.14%，招商证券将评级下调至卖出并给出25港元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1102026058","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102026058?lang=zh_cn&edition=full","pubTime":"2026-08-21 11:04","pubTimestamp":1787281444,"startTime":"0","endTime":"0","summary":"8月21日，巨子生物盘中下跌5.14%，报28.08港元，成交额5620.08万港元。消息面上，招商证券将巨子生物评级从持有下调至卖出，目标价25港元，显著低于当前股价，与此前花旗、东吴证券、国金证券等机构集体维持买入评级形成明显分歧，打压市场情绪。公司8月18日披露的中期业绩显示收入29.18亿元同比下降6.3%，归母净利润9.40亿元同比下降20.5%，核心品牌可复美表现承压，销售费用同比增长近两成。前一交易日股价反弹近5%后，利空评级再度引发抛压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"巨子生物盘中下挫，招商证券罕见下调至卖出","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142041555","title":"异动解读｜巨子生物盘中上涨5.7%，多家券商绩后集体维持买入评级提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1142041555","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142041555?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:50","pubTimestamp":1787190645,"startTime":"0","endTime":"0","summary":"8月20日，巨子生物盘中上涨5.7%，报29.94港元，成交额9724.02万港元。消息面上，公司8月18日盘后发布中期业绩，收入29.18亿元同比下降6.3%，归母净利润9.40亿元同比下降20.5%，业绩公布次日股价一度跌近6%。然而随后多家机构集体力挺：花旗将目标价上调至38.4港元并列为中国化妆品板块首选买入股，东吴证券、国金证券均维持买入评级，认为至暗时刻已过。管理层维持全年收入增长10%及净利润持平的指引，市场情绪在超跌后出现修复。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"巨子生物盘中上涨5.7%，多家券商绩后集体维持买入评级提振情绪","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660442084","title":"可复美失守、业绩连降，巨子生物高增长神话褪色","url":"https://stock-news.laohu8.com/highlight/detail?id=2660442084","media":"北京商报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660442084?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:49","pubTimestamp":1787136580,"startTime":"0","endTime":"0","summary":"从高增长到营利双降，巨子生物的业绩颓势仍未扭转。8月18日晚间，巨子生物发布2026年中期报告，上半年收入29.18亿元，同比下降6.3%；归属于公司权益股东的利润则同比下降20.5%。2025年，巨子生物出现上市以来首次营收、净利润双降，今年上半年颓势不仅未止，净利润降幅反而进一步扩大。核心品牌“可复美”是主要业绩拖累因素。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846429783.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846429783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","02367","BK1207","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660410584","title":"销售费用大增近2成，巨子生物的流量账单越来越贵","url":"https://stock-news.laohu8.com/highlight/detail?id=2660410584","media":"华尔街见闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660410584?lang=zh_cn&edition=full","pubTime":"2026-08-19 14:46","pubTimestamp":1787121971,"startTime":"0","endTime":"0","summary":"8月18日晚，巨子生物发布2026年中期业绩。上半年实现收入29.18亿元，同比下降6.3%；同期净...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3779780","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1207","SG9999004311.SGD","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660041711","title":"【券商聚焦】东吴证券维持巨子生物（02367）买入评级 指至暗时刻已过","url":"https://stock-news.laohu8.com/highlight/detail?id=2660041711","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660041711?lang=zh_cn&edition=full","pubTime":"2026-08-19 14:29","pubTimestamp":1787120961,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券发布研报指，巨子生物 公布2026年上半年业绩，实现营收29.2亿元，同比下滑6.3%；归母净利润9.4亿元，同比下滑20.5%；经调整净利润9.5亿元，同比下滑21.5%。研报认为，短期业绩有所承压，但618大促展现品牌韧性，产品矩阵与医美新品逐步进入兑现期，至暗时刻已过。东吴证券维持2026-2028年归母净利润预测19.78/22.70/26.58亿元，同比分别增长3%/15%/17%，最新收盘价对应2026-2028年PE为13/11/10倍，维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988712","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601555","KCE","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660417197","title":"【券商聚焦】国金证券维持巨子生物（02367）买入评级 指医美新品开启第二曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2660417197","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660417197?lang=zh_cn&edition=full","pubTime":"2026-08-19 14:29","pubTimestamp":1787120954,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券发布研报指，巨子生物 2026年上半年实现营收29.2亿元，同比-6.3%，归母净利润9.4亿元，同比-20.5%。医美业务正式商业化，首款产品753胶原针上市，成功开启第二增长曲线。随着下半年渠道调整逐步到位、护肤品业务在低基数下恢复增长，以及医美新品的持续放量，公司有望重回增长轨道。国金证券预测公司2026/2027/2028年归母净利润为19.81/22.38/25.16亿元，EPS为1.87/2.11/2.37元，对应PE为14/12/11倍，维持“买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988713","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660428061","title":"【东吴商社】巨子生物2026年半年报点评：至暗时刻已过，关注新品及医美业务放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2660428061","media":"草叔消费升级研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660428061?lang=zh_cn&edition=full","pubTime":"2026-08-19 13:50","pubTimestamp":1787118600,"startTime":"0","endTime":"0","summary":"投资要点公司公布2026H1业绩：2026H1公司实现营收29.2亿元，归母净利润9.4亿元，经调整净利润9.5亿元，短期业绩有所承压，但618大促展现品牌韧性，产品矩阵与医美新品逐步进入兑现期。盈利预测与投资评级：公司是我国重组胶原领域引领者，连续三年获欧睿认证为全球重组胶原蛋白领导者，护肤领域品牌力和产品力基本盘稳固，可丽金“753胶原针”及两款重组胶原填充剂陆续获批上市，有望打开医美护肤品业务成长空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzIwMjU2Nzg0MQ==&mid=2247557908&idx=2&sn=e4781276a1489c680060727b6ea89a7c&chksm=9710745df64e89976b34e3f42464cbd089f4ed5315ce6dac0a595ba88d804451d24a177160a8&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["02367","SG9999004311.SGD","LU2488822045.USD","BK1207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660412979","title":"花旗：升巨子生物(02367)目标价至38.4港元 复苏可见度高","url":"https://stock-news.laohu8.com/highlight/detail?id=2660412979","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660412979?lang=zh_cn&edition=full","pubTime":"2026-08-19 11:18","pubTimestamp":1787109492,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，巨子生物目标价由37港元升至38.4港元。收入下跌6%，符合该行预期。报告指，巨子生物管理层维持全年指引，预期收入增长10%及净利润持平，这意味着2026年下半年收入需增长超过30%、净利润需增长超过40%。管理层对达成目标显得非常有信心。该行视巨子生物是其中国化妆品板块的首选买入股，因复苏可见度高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660841679","title":"大行评级丨花旗：升巨子生物目标价至38.4港元，列为中国化妆品板块的首选买入股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660841679","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660841679?lang=zh_cn&edition=full","pubTime":"2026-08-19 10:24","pubTimestamp":1787106260,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["02367","LU2488822045.USD","BK1207","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660416858","title":"港股异动 | 巨子生物(02367)绩后跌近7%  公司主动调整销售结构 上半年纯利同比下滑超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660416858","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660416858?lang=zh_cn&edition=full","pubTime":"2026-08-19 09:44","pubTimestamp":1787103892,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，巨子生物(02367)绩后跌近7%，截至发稿，跌4.34%，报26.88港元，成交额8868.63万港元。消息面上，巨子生物发布业绩，上半年收入约29.18亿元，同比减少6.3%；归母净利润9.4亿元，同比减少20.5%。国金证券发布研报称，公司业绩短期承压主要系公司主动进行销售结构调整，聚焦长期经营质量所致。尽管整体收入有所下滑，但公司核心品牌618大促期间表现亮眼，可复美与可丽金线上全渠道GMV分别同比增长超过25%和超过30%，复苏拐点已现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1207","02367","SG9999004311.SGD","VXUS","BK4585","KCAI","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133098696","title":"异动解读｜巨子生物盘中下跌5.48%，中期业绩收入及净利双降","url":"https://stock-news.laohu8.com/highlight/detail?id=1133098696","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133098696?lang=zh_cn&edition=full","pubTime":"2026-08-19 09:40","pubTimestamp":1787103658,"startTime":"0","endTime":"0","summary":"8月19日，巨子生物盘中下跌5.48%，报26.36港元，成交额7367.92万港元。消息面上，公司于8月18日盘后发布中期业绩，收入29.18亿元，同比下降6.3%；毛利23.18亿元，同比下降8.8%；归属于公司权益股东利润9.40亿元，同比下降20.5%；经调整净利润9.46亿元，同比下降21.5%。业绩全面下滑，叠加此前同行上美股份预告中期利润大跌76.6%-78.4%引发的板块盈利担忧，市场情绪持续承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"巨子生物盘中下跌5.48%，中期业绩收入及净利双降","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660182469","title":"巨子生物：上半年权益股东应占利润达9.4亿元 同比降20.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660182469","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660182469?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:17","pubTimestamp":1787048220,"startTime":"0","endTime":"0","summary":"8月18日，巨子生物（02367）发布2026年中期业绩，公司收入为29.18亿元，同比下降6.3%；毛利为23.18亿元，同比下降8.8%；税前利润为10.95亿元，同比下降24.2%；归属于公司权益股东利润为9.4亿元，同比下降20.5%；每股基本盈利为0.89元，同比下降21.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183844670158.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608183844670158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","SG9999004311.SGD","BK1207","02367"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xajuzi.com","stockEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0497},{"period":"6month","weight":-0.1097},{"period":"1year","weight":-0.534},{"period":"ytd","weight":-0.1809}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.0188},{"period":"1year","weight":-0.0002},{"period":"ytd","weight":-0.0085}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"巨子生物控股有限公司是一家主要从事基于生物活性成分的美丽与健康产品的研发、制造及销售业务的投资控股公司。该公司的主要产品包括功效性护肤品、医用敷料等专业皮肤护理产品，以及保健食品及其他产品。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.063748},{"month":2,"riseRate":0.75,"avgChangeRate":0.082293},{"month":3,"riseRate":0.75,"avgChangeRate":0.04973},{"month":4,"riseRate":0.75,"avgChangeRate":0.023756},{"month":5,"riseRate":0.25,"avgChangeRate":-0.038833},{"month":6,"riseRate":0.25,"avgChangeRate":-0.059254},{"month":7,"riseRate":0.5,"avgChangeRate":0.005281},{"month":8,"riseRate":0.5,"avgChangeRate":-0.026722},{"month":9,"riseRate":0.75,"avgChangeRate":0.04866},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.12614},{"month":11,"riseRate":0.333333,"avgChangeRate":0.019826},{"month":12,"riseRate":0.25,"avgChangeRate":0.047111}],"exchange":"SEHK","name":"巨子生物","nameEN":"GIANT BIOGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"巨子生物,02367,巨子生物股票,巨子生物股票老虎,巨子生物股票老虎国际,巨子生物行情,巨子生物股票行情,巨子生物股价,巨子生物股市,巨子生物股票价格,巨子生物股票交易,巨子生物股票购买,巨子生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}